US9796708, Example 1119

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: US9796708, Example 1119
• 英文别名: [(2R)-4-[4-(5-fluoro-2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1,2,3,6-tetrahydropyridin-2-yl]methanol
• 化学式: C₂₀H₂₀FN₃O₂
• 分子量: 353.4
• InChiKey: WTCATEFCXLZNCB-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  70.2
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRROLO[2,3-B]PYRIDINE CDK9 KINASE
  申请人：ABBVIE INC

  公开号：WO2014139328A1

  公开（公告）日：2014-09-18

  Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

  公开的是Formula (IIa)的化合物，其中R1、R2、R3A、R3B、R3C、R3D、R3E和R4如规范中所定义，并且其药用盐。这些化合物可用作治疗疾病，包括癌症的药物。还提供了包含一个或多个Formula (IIa)化合物的药物组合物。
• PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS
  申请人：ABBVIE INC.

  公开号：US20160060257A1

  公开（公告）日：2016-03-03

  Disclosed are compounds of Formula (IIa), wherein R 1 , R 2 , R 3A , R 3B , R 3C , R 3D , R 3E , and R 4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

  本发明涉及公式（IIa）的化合物，其中R1、R2、R3A、R3B、R3C、R3D、R3E和R4如规范中所定义，以及其药学上可接受的盐。这些化合物可用作治疗疾病，包括癌症的药剂。还提供了包含一个或多个公式（IIa）化合物的制药组合物。
• Quinoline derivatives for treating infections with helminths
  申请人：Bayer Animal Health GMBH

  公开号：US11254661B2

  公开（公告）日：2022-02-22

  The present invention covers quinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.

  本发明涉及通式（I）的喹啉化合物（其中 A、R1、R2、R3、R4、R5、R6 和 Q 如本文所定义）、制备所述化合物的方法、用于制备所述化合物的中间体化合物、包含所述化合物的药物组合物和组合物，以及使用所述化合物制造用于治疗、控制和/或预防疾病（尤其是蠕虫感染）的药物组合物，作为单独制剂或与其他活性成分组合使用。
• Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
  申请人：Bantam Pharmaceutical, LLC

  公开号：US11325903B2

  公开（公告）日：2022-05-10

  Disclosed are compounds useful, for example, in methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formulae (Ia), (Ib), (Ic), (Id) and (Ie), in which R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.

  本发明公开了一些化合物，例如用于治疗癌症等增殖过快疾病的方法、阻止癌细胞细胞周期的方法、抑制癌细胞谷胱甘肽合成的方法，以及相关化合物在药物中的用途和使用方法。在某些实施方案中，所述方法、用途和化合物参照结构式（Ia）、（Ib）、（Ic）、（Id）和（Ie）的化合物提供，其中R1、L1、L2、Q、L3、R3、L4、R4、L5和R5如本文所述。在某些实施方案中，本文公开的化合物对具有突变 KRAS 基因的癌症特别有效。
• PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS
  申请人：AbbVie Inc.

  公开号：EP2970278A1

  公开（公告）日：2016-01-20